{
    "id": 23339,
    "fullName": "ERBB2 G292R",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) G292R lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G292R results in increased cell growth in culture (PMID: 24997986) and therefore, is predicted to lead to a gain of Erbb2 (Her2) protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 7076,
                    "pubMedId": 24997986,
                    "title": "Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24997986"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "G292R",
    "createDate": "06/16/2016",
    "updateDate": "04/15/2019",
    "referenceTranscriptCoordinates": {
        "id": 170495,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39710454G>C",
        "cDna": "c.874G>C",
        "protein": "p.G292R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13204,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) G292R (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 24027,
                "profileName": "ERBB2 G292R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24027,
            "profileName": "ERBB2 G292R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170496,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39710454G>C",
            "cDna": "c.874G>C",
            "protein": "p.G292R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170495,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39710454G>C",
            "cDna": "c.874G>C",
            "protein": "p.G292R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}